SCHEMBL17292962

SCHEMBL17292962

COC(C)c1c(C(=O)OC(C)(C)C)cnc2cc(F)nn12

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MALT1 Q9UDY8 17/20 0.40
▸ BIRC3 Q13489 2/20 0.40
▸ FPR2 P25090 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ HTR7 P34969 1/20 0.33
▸ TMEM97 Q5BJF2 1/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ P2RX3 P56373 1/20 0.33
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17292964 1.00 MALT1 (0.40) MALT1BIRC3FPR2SCN9AHTR7
SCHEMBL18863076 0.87 MALT1 (0.37) MALT1BIRC3HTR7TMEM97SIGMAR1
SCHEMBL17293077 0.87 MALT1 (0.49) MALT1BIRC3CYP1A2
SCHEMBL17293075 0.87 MALT1 (0.49) MALT1BIRC3CYP1A2
SCHEMBL17293034 0.86 MALT1 (0.51) MALT1BIRC3HTR7TMEM97SIGMAR1
SCHEMBL17293032 0.86 MALT1 (0.51) MALT1BIRC3HTR7TMEM97SIGMAR1
SCHEMBL17293002 0.84 MALT1 (0.41) MALT1BIRC3HTR7TMEM97SIGMAR1
SCHEMBL17293001 0.84 MALT1 (0.41) MALT1BIRC3HTR7TMEM97SIGMAR1
SCHEMBL17293107 0.76 MALT1 (0.50) MALT1BIRC3
SCHEMBL17293109 0.76 MALT1 (0.50) MALT1BIRC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200289514-A1 Novel Pyrazolo Pyrimidine Derivatives NOVARTIS PHARMA AG (CH) 2020-09-17 — — US disclosed
US-10442808-B2 Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors NOVARTIS AG (CH) 2019-10-15 — — US disclosed
EP-3149001-B1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS NOVARTIS AG (CH) 2019-04-24 — — EP disclosed
EP-3374361-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2018-09-19 — — EP disclosed
US-20180030061-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS NOVARTIS AG (CH) 2018-02-01 — — US disclosed
US-9815842-B2 Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors NOVARTIS AG (CH) 2017-11-14 — — US disclosed
WO-2017081641-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2017-05-18 — — WO disclosed
US-20170121335-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS NOVARTIS AG (CH) 2017-05-04 — — US disclosed
EP-3149001-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS Novartis AG (CH) 2017-04-05 — — EP disclosed
WO-2015181747-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS NOVARTIS AG (CH) 2015-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030061-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS MMEL1, MALT1, FBP1 MALT1 2/4885BIRC3 13/4885FPR2 2539/4885
US-20200289514-A1 Novel Pyrazolo Pyrimidine Derivatives MMEL1, PPME1, CTSC MALT1 4/4885BIRC3 49/4885FPR2 2779/4885
US-20170121335-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHBITORS MMEL1, MALT1, FBP1 MALT1 2/4885BIRC3 13/4885FPR2 2539/4885
US-10442808-B2 Pyrazolo pyrimidine derivatives and their use as MALT1 inhbitors FBP1, MMEL1, MALT1 MALT1 3/4885BIRC3 40/4885FPR2 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback